Collapsin Response-Mediator Protein-5-IgG, Western Blot, Spinal Fluid
Use
The CRMP-5-IgG test is useful for evaluating cases of subacute chorea, vision loss, cranial neuropathy, and myelopathy. It detects autoantibodies specific for neurons and muscle, which are significant serological markers of neurological autoimmunity. These autoantibodies are often predictive of neoplasms such as small-cell lung carcinomas (SCLC) and thymoma. CRMP-5-IgG is a more common autoantibody accompaniment of SCLC than antineuronal nuclear antibodies-1 (ANNA-1; anti-Hu) and may occur with thymoma. The test is indicated particularly when interfering autoantibodies preclude identification by standard immunofluorescence.
Special Instructions
Not provided.
Limitations
CRMP-5-IgG may not be detectable by standard immunofluorescence if the titer is low or if coexisting autoantibodies obscure detection. The test uses a Western blot analysis, which is effective when standard assays are ambiguous or negative in the presence of suggestive neurological symptoms.
New York Approved
Methodology
Immunoassay (Western Blot)
Biomarkers
CRMP-5
Protein
LOINC Codes
- 53707-6 - CV2 IgG CSF Ql IB
- 53707-6 - CV2 IgG CSF Ql IB
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
3 mL
Minimum Volume
2 mL
Container
Sterile vial
Storage Instructions
Send specimen refrigerated.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |